In a bullish take on current circumstances, Morgan Stanley’s head of U.S. equity strategy argued in a recent note to clients that the current state of the market appears remarkably similar to that of March 2009, when the S&P 500 began the longest-running bull market in history. With this view in mind, risk-tolerant investors may want to identify compelling yet affordable names, especially in the biotech space. Today’s article highlights three such biotech stocks, all of which have earned “Strong Buy” consensus ratings, are trading for under $5, and sport “colossal upside potential.” For more, CLICK HERE.